Identification, isolation, characterization, and UHPLC quantification of potential genotoxic impurities in linagliptin
- 29 August 2018
- journal article
- research article
- Published by Wiley in Journal of Separation Science
- Vol. 41 (21) , 3985-3994
Abstract
During the stress testing of linagliptin, one unknown degradation product (impurity I) on acidic conditions was detected by using high‐performance liquid chromatography and subsequently isolated, identified, and characterized by the spectral data (MS, MS/MS, 1D and 2D NMR spectroscopy, and IR spectroscopy) and finally subjected for mechanism analysis. The degradation product (impurity I) and another process‐related impurity (impurity II) of linagliptin were found to contain the structural alerts of N‐acylated aminoaryl and alkyl halide, respectively, which were both potential genotoxic substances. Hence, a rapid and facile ultra high performance liquid chromatography method was developed for the simultaneous determination of these two potential genotoxic impurities at ppm levels in linagliptin. The factors involved in the method development were discussed and this method was fully validated as per International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines, which proved the method sensitive, selective, and robust. The presented method has been successfully applied to the analysis of real samples from multiple batches. This study will help to risk management of possible genotoxic impurities present in linagliptin.Keywords
Funding Information
- Jiangsu Food and Drug Administration
This publication has 16 references indexed in Scilit:
- Stability-Indicating HPLC-DAD Method for the Determination of Linagliptin in Tablet Dosage Form: Application to Degradation KineticsJournal of Chromatographic Science, 2016
- UPLC simultaneous determination of empagliflozin, linagliptin and metforminRSC Advances, 2015
- LC–MS/MS and NMR Characterization of Key Impurities in Linagliptin and PramipexoleJournal of Liquid Chromatography & Related Technologies, 2015
- Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: A comprehensive reviewJournal of Separation Science, 2015
- Simultaneous determination of linagliptin and metformin by reverse phase-high performance liquid chromatography method: An application in quantitative analysis of pharmaceutical dosage formsJournal of Advanced Pharmaceutical Technology & Research, 2015
- Strategies for the identification, control and determination of genotoxic impurities in drug substances: A pharmaceutical industry perspectiveJournal of Pharmaceutical and Biomedical Analysis, 2011
- Overview of Genotoxic Impurities in Pharmaceutical DevelopmentInternational Journal of Toxicology, 2009
- Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs)Journal of Pharmaceutical and Biomedical Analysis, 2008
- 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 DiabetesJournal of Medicinal Chemistry, 2007
- A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityRegulatory Toxicology and Pharmacology, 2006